Article
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing.
JCO precision oncology - 1 Sept 2023
Napolitano Stefania, Parikh Aparna R, Henry Jason, Parseghian Christine M, Willis Jason, Raghav Kanwal P, Morris Van K, Johnson Benny, Kee Bryan K, Dasari Arvind N, Overman Michael J, Luthra Raja, Drusbosky Leylah M, Corcoran Ryan B, Kopetz Scott, Sun Ryan
Abstract excerpt
PURPOSE: In metastatic colorectal cancer, the detection of RAS mutations by circulating tumor DNA (ctDNA) has emerged as a valid and noninvasive alternative approach to determining RAS status. However, some RAS mutations may be missed, that is, false negatives can occur, possibly compromising important treatment decisions. We propose a statistical model to assess the probability of false negatives when performing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.